Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19. DESIGN: FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study. SETTING: Twelve clinical sites in France (ICU and gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvelli, Julien, Meziani, Ferhat, Dellamonica, Jean, Cordier, Pierre-Yves, Allardet-Servent, Jerome, Fraisse, Megan, Velly, Lionel, Barbar, Saber Davide, Lehingue, Samuel, Guervilly, Christophe, Desgrouas, Maxime, Camou, Fabrice, Piperoglou, Christelle, Vely, Frederic, Demaria, Olivier, Karakunnel, Joyson, Fares, Joanna, Batista, Luciana, Rotolo, Federico, Viotti, Julien, Boyer-Chammard, Agnes, Lacombe, Karine, Le Dault, Erwan, Carles, Michel, Schleinitz, Nicolas, Vivier, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674430/
https://www.ncbi.nlm.nih.gov/pubmed/36218354
http://dx.doi.org/10.1097/CCM.0000000000005683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674430/
https://www.ncbi.nlm.nih.gov/pubmed/36218354
http://dx.doi.org/10.1097/CCM.0000000000005683

Ejemplares similares